04:32 PM EST, 11/21/2025 (MT Newswires) -- C4 Therapeutics ( CCCC ) filed a shelf registration statement with the US Securities and Exchange Commission on late Friday for the potential sale of up to $400 million in securities, to be offered from time to time.

The filing covers common stock, preferred stock, debt securities, warrants and units.

The company said the offering proceeds will be used primarily to support research and development, and operations, with flexibility for other corporate purposes as needed.